CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Dynavax Technologies Corporation - DVAX CFD

    13.25
    1.27%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.08
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Dynavax Technologies Corp ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 13.42
    Open* 13.24
    1-Year Change* 15.13%
    Day's Range* 13.24 - 13.39
    52 wk Range 9.42-15.15
    Average Volume (10 days) 1.52M
    Average Volume (3 months) 32.96M
    Market Cap 1.75B
    P/E Ratio 36.71
    Shares Outstanding 129.26M
    Revenue 361.18M
    EPS 0.37
    Dividend (Yield %) N/A
    Beta 1.36
    Next Earnings Date Feb 21, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 8, 2023 13.25 0.02 0.15% 13.23 13.44 13.14
    Dec 7, 2023 13.42 0.14 1.05% 13.28 13.51 13.24
    Dec 6, 2023 13.36 -0.33 -2.41% 13.69 13.78 13.31
    Dec 5, 2023 13.71 0.04 0.29% 13.67 13.76 13.49
    Dec 4, 2023 13.88 0.27 1.98% 13.61 13.93 13.60
    Dec 1, 2023 13.75 0.26 1.93% 13.49 13.85 13.45
    Nov 30, 2023 13.68 0.35 2.63% 13.33 13.79 13.33
    Nov 29, 2023 13.31 0.11 0.83% 13.20 13.41 13.14
    Nov 28, 2023 13.22 -0.19 -1.42% 13.41 13.48 13.08
    Nov 27, 2023 13.57 0.19 1.42% 13.38 13.60 13.26
    Nov 24, 2023 13.53 0.00 0.00% 13.53 13.66 13.43
    Nov 22, 2023 13.44 -0.10 -0.74% 13.54 13.65 13.35
    Nov 21, 2023 13.51 0.03 0.22% 13.48 13.72 13.43
    Nov 20, 2023 13.64 0.21 1.56% 13.43 13.78 13.43
    Nov 17, 2023 13.47 -0.05 -0.37% 13.52 13.69 13.34
    Nov 16, 2023 13.47 0.30 2.28% 13.17 13.49 13.17
    Nov 15, 2023 13.51 0.02 0.15% 13.49 13.95 13.48
    Nov 14, 2023 13.77 -0.12 -0.86% 13.89 14.05 13.63
    Nov 13, 2023 13.49 0.47 3.61% 13.02 13.52 12.98
    Nov 10, 2023 13.13 0.10 0.77% 13.03 13.24 12.83

    Dynavax Technologies Corporation Events

    Time (UTC) Country Event
    Wednesday, February 21, 2024

    Time (UTC)

    21:00

    Country

    US

    Event

    Q4 2023 Dynavax Technologies Corp Earnings Release
    Q4 2023 Dynavax Technologies Corp Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 722.683 439.442 46.551 35.219 8.198
    Revenue 722.683 439.442 46.551 35.219 8.198
    Total Operating Expense 439.161 310.188 114.922 170.062 161.517
    Selling/General/Admin. Expenses, Total 129.185 98.25 76.96 76.815 61.978
    Research & Development 46.6 32.228 28.607 62.331 74.951
    Unusual Expense (Income) 1.223 6.138 -4.555 11.527 2.792
    Operating Income 283.522 129.254 -68.371 -134.843 -153.319
    Interest Income (Expense), Net Non-Operating 2.881 -61.29 -12.878 -21.307 -5.21
    Other, Net 7.896 9.557 6.009 3.55 -0.37
    Net Income Before Taxes 294.299 77.521 -75.24 -152.6 -158.899
    Net Income After Taxes 293.156 76.713 -75.24 -152.6 -158.899
    Net Income Before Extra. Items 293.156 76.713 -75.24 -152.6 -158.899
    Net Income 293.156 76.713 -75.24 -152.6 -158.899
    Income Available to Common Excl. Extra. Items 292.873 72.144 -75.24 -155.867 -158.899
    Income Available to Common Incl. Extra. Items 292.873 72.144 -75.24 -155.867 -158.899
    Diluted Net Income 292.873 72.144 -75.24 -155.867 -158.899
    Diluted Weighted Average Shares 150.797 133.006 100.753 72.024 62.362
    Diluted EPS Excluding Extraordinary Items 1.94217 0.54241 -0.74678 -2.1641 -2.54801
    Diluted Normalized EPS 1.95025 0.58808 -0.79199 -2.00405 -2.50324
    Other Operating Expenses, Total
    Total Extraordinary Items
    Cost of Revenue, Total 262.153 173.572 13.91 19.389 21.796
    Gross Profit 460.53 265.87 32.641 15.83 -13.598
    Total Adjustments to Net Income -0.283 -4.569 -3.267
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 60.249 46.925 184.492 167.735 256.464
    Revenue 60.249 46.925 184.492 167.735 256.464
    Cost of Revenue, Total 13.537 14.712 77.488 61.334 83.369
    Gross Profit 46.712 32.213 107.004 106.401 173.095
    Total Operating Expense 63.654 77.173 121.357 106.338 128.237
    Selling/General/Admin. Expenses, Total 36.174 48.152 30.382 31.604 35.735
    Research & Development 13.046 13.605 12.854 12.962 9.689
    Unusual Expense (Income) 0.897 0.704 0.633 0.438 -0.556
    Operating Income -3.405 -30.248 63.135 61.397 128.227
    Interest Income (Expense), Net Non-Operating 5.69 4.911 2.64 0.877 -0.918
    Other, Net 1.922 1.621 2.199 1.818 2.065
    Net Income Before Taxes 4.207 -23.716 67.974 64.092 129.374
    Net Income After Taxes 3.431 -24.332 67.733 63.809 128.755
    Net Income Before Extra. Items 3.431 -24.332 67.733 63.809 128.755
    Net Income 3.431 -24.332 67.733 63.809 128.755
    Income Available to Common Excl. Extra. Items 3.431 -24.332 67.45 63.809 128.755
    Income Available to Common Incl. Extra. Items 3.431 -24.332 67.45 63.809 128.755
    Diluted Net Income 3.431 -24.332 67.45 63.809 128.755
    Diluted Weighted Average Shares 152.142 127.921 151.889 151.538 149.905
    Diluted EPS Excluding Extraordinary Items 0.02255 -0.19021 0.44407 0.42108 0.85891
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS 0.02736 -0.18663 0.44823 0.42395 0.85522
    Total Adjustments to Net Income -0.283
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 916.985 972.52 290.015 208.653 174.364
    Cash and Short Term Investments 624.395 545.95 165.036 151.055 145.536
    Cash & Equivalents 202.004 436.189 32.073 39.884 49.348
    Short Term Investments 422.391 109.761 132.963 111.171 96.188
    Total Receivables, Net 147.515 131.816 22.661 8.886 3.704
    Accounts Receivable - Trade, Net 145.13 116.216 22.661 8.886 3.704
    Prepaid Expenses 85.629 233.419 38.629 7.38 6.102
    Total Assets 985.85 1039.25 353.272 279.068 210.884
    Property/Plant/Equipment, Total - Net 63.341 60.984 57.15 62.274 17.064
    Property/Plant/Equipment, Total - Gross 90.863 86.362 80.561 80.261 40.213
    Accumulated Depreciation, Total -27.522 -25.378 -23.411 -17.987 -23.149
    Goodwill, Net 2.006 2.125 2.297 2.081 2.144
    Other Long Term Assets, Total 3.518 3.617 3.81 3.56 5.595
    Total Current Liabilities 150.074 556.402 77.411 53.047 38.033
    Accounts Payable 3.211 2.6 3.312 9.278 5.278
    Accrued Expenses 146.863 185.909 25.151 21.961 25.755
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0 367.893 48.948 21.808 7
    Total Liabilities 404.837 816.872 294.579 270.778 147.819
    Total Long Term Debt 221.578 220.49 179.811 178.601 100.871
    Other Liabilities, Total 33.185 39.98 37.357 39.13 8.915
    Total Equity 581.013 222.374 58.693 8.29 63.065
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Common Stock 0.128 0.123 0.11 0.084 0.063
    Additional Paid-In Capital 1510.52 1441.87 1352.37 1229.42 1131.24
    Retained Earnings (Accumulated Deficit) -924.195 -1217.35 -1294.06 -1218.82 -1066.22
    Other Equity, Total -5.438 -2.266 0.273 -2.387 -2.015
    Total Liabilities & Shareholders’ Equity 985.85 1039.25 353.272 279.068 210.884
    Total Common Shares Outstanding 127.604 122.945 110.19 83.871 62.862
    Total Inventory 59.446 61.335 63.689 41.332 19.022
    Other Current Assets, Total 0
    Intangibles, Net 0 2.5 11.717
    Long Term Debt 221.578 220.49 179.811 178.601 100.871
    Total Preferred Shares Outstanding 0 0 0.004 0.005
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 835.666 797.46 830.141 916.985 932.944
    Cash and Short Term Investments 720.416 681.525 651.956 624.395 586.486
    Cash & Equivalents 154.511 226.823 174.35 202.004 198.576
    Short Term Investments 565.905 454.702 477.606 422.391 387.91
    Total Receivables, Net 46.866 45.353 104.866 147.515 131.118
    Accounts Receivable - Trade, Net 46.347 43.245 101.738 145.13 129.772
    Total Inventory 49.412 53.088 57.693 59.446 102.609
    Prepaid Expenses 18.972 17.494 15.626 85.629 112.731
    Total Assets 972.933 936.432 969.922 985.85 999.337
    Property/Plant/Equipment, Total - Net 61.132 62.808 63.592 63.341 61.032
    Goodwill, Net 1.981 2.039 2.038 2.006 1.835
    Other Long Term Assets, Total 74.154 74.125 74.151 3.518 3.526
    Total Current Liabilities 54.264 44.862 91.515 150.074 244.08
    Accounts Payable 3.12 3.246 7.296 3.211 3.05
    Accrued Expenses 51.144 41.616 84.219 146.863 153.629
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0 87.401
    Total Liabilities 368.017 359.227 406.19 404.837 498.761
    Total Long Term Debt 222.415 222.134 221.855 221.578 221.303
    Long Term Debt 222.415 222.134 221.855 221.578 221.303
    Other Liabilities, Total 91.338 92.231 92.82 33.185 33.378
    Total Equity 604.916 577.205 563.732 581.013 500.576
    Preferred Stock - Non Redeemable, Net
    Common Stock 0.129 0.129 0.128 0.128 0.127
    Additional Paid-In Capital 1541.55 1527.54 1516.33 1510.52 1501.64
    Retained Earnings (Accumulated Deficit) -930.803 -945.096 -948.527 -924.195 -991.928
    Other Equity, Total -5.959 -5.372 -4.2 -5.438 -9.262
    Total Liabilities & Shareholders’ Equity 972.933 936.432 969.922 985.85 999.337
    Total Common Shares Outstanding 129.195 128.779 128.472 127.604 127.581
    Total Preferred Shares Outstanding 0 0 0 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 293.156 76.713 -75.24 -152.6 -158.899
    Cash From Operating Activities 62.716 335.528 -92.251 -121.252 -131.301
    Cash From Operating Activities 3.812 4.296 4.273 8.938 3.621
    Amortization 0 0 2.5 9.217 10.862
    Non-Cash Items 64.165 82.299 9.13 46.859 24.772
    Cash Interest Paid 5.638 9.815 16.541 12.147 6.583
    Changes in Working Capital -298.417 172.22 -32.914 -33.666 -11.657
    Cash From Investing Activities -315.995 14.225 -26.532 -42.782 55.466
    Capital Expenditures -7.139 -9.477 -11.072 -29.401 -15.187
    Other Investing Cash Flow Items, Total -308.856 23.702 -15.46 -13.381 70.653
    Cash From Financing Activities 19.525 55.776 109.499 154.351 99.071
    Financing Cash Flow Items 1.431 0.841 0.672 0.565 0.594
    Issuance (Retirement) of Stock, Net 18.094 25.307 108.827 79.536 -0.523
    Issuance (Retirement) of Debt, Net 0 29.628 0 74.25 99
    Foreign Exchange Effects -0.443 -1.431 1.494 -0.184 -0.482
    Net Change in Cash -234.197 404.098 -7.79 -9.867 22.754
    Cash Taxes Paid 2.208 1.312
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -24.332 293.156 225.423 161.614 32.859
    Cash From Operating Activities 27.622 62.716 27.768 -33.792 -50.443
    Cash From Operating Activities 1.013 3.812 2.975 2.085 0.985
    Amortization 0
    Non-Cash Items 21.177 64.165 38.369 14.46 8.087
    Cash Interest Paid 5.638 2.819 2.819 0
    Changes in Working Capital 29.764 -298.417 -238.999 -211.951 -92.374
    Cash From Investing Activities -52.334 -315.995 -283.028 -163.981 -216.483
    Capital Expenditures -1.283 -7.139 -5.552 -4.271 -1.358
    Other Investing Cash Flow Items, Total -51.051 -308.856 -277.476 -159.71 -215.125
    Cash From Financing Activities -3.09 19.525 19.372 11.315 10.287
    Financing Cash Flow Items -3.329 1.431 1.43 0.71 0.71
    Issuance (Retirement) of Stock, Net 0.239 18.094 17.942 10.605 9.577
    Foreign Exchange Effects 0.151 -0.443 -1.755 -0.657 -0.134
    Net Change in Cash -27.651 -234.197 -237.643 -187.115 -256.773
    Issuance (Retirement) of Debt, Net 0 0 0
    Cash Taxes Paid 0.032 2.208 0.788 0.509 0.087
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    BlackRock Institutional Trust Company, N.A. Investment Advisor 13.6555 17587958 291613 2023-06-30 LOW
    Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund 9.7947 12615363 0 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 6.8741 8853640 425263 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 6.047 7788367 -1155281 2023-06-30 LOW
    Deep Track Capital LP Hedge Fund 5.0916 6557816 1636 2023-06-30 MED
    Chicago Capital, LLC Investment Advisor 4.4968 5791735 -18733 2023-09-30 LOW
    Fisher Investments Investment Advisor/Hedge Fund 3.0287 3900949 -63576 2023-06-30 LOW
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 2.748 3539385 607658 2023-06-30 LOW
    Goldman Sachs & Company, Inc. Research Firm 2.625 3380967 -150507 2023-06-30 MED
    PFM Health Sciences, LP Hedge Fund 2.1001 2704917 -1100453 2023-06-30 MED
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.9545 2517400 203425 2023-06-30 LOW
    William Blair & Company, L.L.C. (Research) Research Firm 1.9062 2455132 -74687 2023-06-30 LOW
    Citadel Advisors LLC Hedge Fund 1.9039 2452144 2356237 2023-06-30 LOW
    Bain Capital Life Sciences Investors, LLC Investment Advisor 1.875 2415000 -1500000 2023-06-30 LOW
    Renaissance Technologies LLC Hedge Fund 1.5348 1976732 -669577 2023-06-30 HIGH
    Rock Springs Capital Management LP Hedge Fund 1.4082 1813758 0 2023-06-30 LOW
    Woodline Partners LP Hedge Fund 1.3839 1782398 1716617 2023-06-30 HIGH
    Edmond de Rothschild Asset Management (France) S.A. Investment Advisor 1.285 1655000 -350000 2023-06-30 LOW
    Two Sigma Investments, LP Hedge Fund 1.196 1540364 -191822 2023-06-30 HIGH
    Morgan Stanley & Co. LLC Research Firm 1.1327 1458836 -120744 2023-06-30 MED

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Dynavax Technologies Corporation Company profile

    Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body''s innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19; and collaboration with Medicago to develop a novel adjuvanted COVID 19 vaccine candidate. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.
    Industry: Bio Therapeutic Drugs

    2100 Powell Street
    Suite 720
    EMERYVILLE
    CALIFORNIA 94608
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    XRP/USD

    0.63 Price
    -6.600% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Gold

    1,996.96 Price
    -0.400% 1D Chg, %
    Long position overnight fee -0.0199%
    Short position overnight fee 0.0117%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    BTC/USD

    42,218.15 Price
    -4.110% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    US100

    16,039.80 Price
    -0.230% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading